A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico

This was a double-blind, randomized, controlled, phase II clinical trial, two dose study of re-derived, live-attenuated, tetravalent dengue virus (TDEN) vaccine (two formulations) or placebo in subjects 1–50 years of age. Among the 636 subjects enrolled, 331 (52%) were primed, that is, baseline sero...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Kristen, Esquilin, Ines O., Cornier, Alberto Santiago, Thomas, Stephen J., Quintero del Rio, Ana I., Bertran-Pasarell, Jorge, Morales Ramirez, Javier O., Diaz, Clemente, Carlo, Simon, Eckels, Kenneth H., Tournay, Elodie, Toussaint, Jean-Francois, De La Barrera, Rafael, Fernandez, Stefan, Lyons, Arthur, Sun, Wellington, Innis, Bruce L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559678/
https://www.ncbi.nlm.nih.gov/pubmed/26175027
http://dx.doi.org/10.4269/ajtmh.14-0625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559678/
https://www.ncbi.nlm.nih.gov/pubmed/26175027
http://dx.doi.org/10.4269/ajtmh.14-0625

Ejemplares similares